VivoSim Seeks Approval for Reverse Split, Equity Plan Increase, and Warrant Share Issuance
VIVS is trading near its 52-week low of $0.263 (9.0% above the low) on light trading volume (0.1× avg).
Summary
VivoSim's definitive proxy sets a September 30 vote on a reverse split, a 3.165M share equity plan increase, and issuance of 4.7M warrant shares with a reduced exercise price.
Key Events · Corporate Governance and Compliance · VIVS
-
Reverse Stock Split Vote
Stockholders will vote on a reverse split at a ratio between 1-for-5 and 1-for-20, with the board authorized to implement it any time before September 30, 2027. At 1-for-20, outstanding shares would drop from 16.6M to about 829,000.
-
Equity Plan Share Increase
Proposal 5 seeks to add 3,165,000 shares to the 2022 Equity Incentive Plan, representing about 19% of current outstanding shares. The company says the reserve is expected to last four years.
-
Warrant Share Issuance and Repricing
Proposal 6 asks approval for 4,705,883 common warrant shares and a reduction of the May 2024 Investor Warrant exercise price from $9.60 to $0.85. Full exercise would dilute existing holders by approximately 23.85%.
-
Nasdaq Compliance Context
The warrant proposal is required by Nasdaq Listing Rule 5635(d) and the July 2026 PIPE terms. The company regained Nasdaq compliance in August 2026 after a delisting notice in July.
Analysis · VIVS · Life Sciences
The definitive proxy for the September 30 annual meeting adds two material proposals beyond the reverse stock split already previewed in the preliminary filing: a 3.165 million share increase to the equity incentive plan and approval for 4.7 million warrant shares plus a warrant exercise price reduction from $9.60 to $0.85. The warrant proposal is required by Nasdaq rules and the July 2026 PIPE terms; if approved, it would dilute existing holders by roughly 23.85%. The reverse split, if enacted at up to 1-for-20, would shrink the share count from 16.6 million to as low as 829,000, boosting the per-share price but leaving authorized shares unchanged, creating significant future issuance headroom. These votes are pivotal for the company's capital structure and Nasdaq compliance.
At the time of this filing, VIVS was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.26 to $5.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.